Laboratory testing for mitochondrial diseases: biomarkers for diagnosis and follow-up

Abstract

The currently available biomarkers generally lack the specificity and sensitivity needed for the diagnosis and follow-up of patients with mitochondrial diseases (MDs). In this group of rare genetic disorders (mutations in approximately 350 genes associated with MDs), all clinical presentations, ages of disease onset and inheritance types are possible. Blood, urine, and cerebrospinal fluid surrogates are well-established biomarkers that are used in clinical practice to assess MD. One of the main challenges is validating specific and sensitive biomarkers for the diagnosis of disease and prediction of disease progression. Profiling of lactate, amino acids, organic acids, and acylcarnitine species is routinely conducted to assess MD patients. New biomarkers, including some proteins and circulating cell-free mitochondrial DNA, with increased diagnostic specificity have been identified in the last decade and have been proposed as potentially useful in the assessment of clinical outcomes. Despite these advances, even these new biomarkers are not sufficiently specific and sensitive to assess MD progression, and new biomarkers that indicate MD progression are urgently needed to monitor the success of novel therapeutic strategies. In this report, we review the mitochondrial biomarkers that are currently analyzed in clinical laboratories, new biomarkers, an overview of the most common laboratory diagnostic techniques, and future directions regarding targeted versus untargeted metabolomic and genomic approaches in the clinical laboratory setting. Brief descriptions of the current methodologies are also provided.

Keywords:

• Mitochondrial diseases
• biomarkers
• laboratory diagnosis
• metabolomics
• mass spectrometry

Disclosure statement

The authors report there are no competing interests to declare.

Additional information

Funding

This work has been funded by the “Instituto de Salud Carlos III” (PI20/00340) (co-funded by European Regional Development Fund “A way to make Europe”), FEDER 2014–2020, and “Asociación de Enfermos de Patologías Mitocondriales (AEPMI)”. CIBERER is an initiative of the “Instituto de Salud Carlos III”.